TCEAL7: A Potential Drug Target and Biomarker for Transcription Elongation Factor S-II

Target Name: TCEAL7

NCBI ID: G56849

TCEAL7

TCEAL7: A Potential Drug Target and Biomarker for Transcription Elongation Factor S-II

Abstract:
Transcription elongation factor S-II (TCEAL7) is a key regulator of gene expression in eukaryotic cells. The S-II complex plays a crucial role in elongating DNA secondary structure, thereby providing a stable binding site for RNA polymerase. The gene coding region of TCEAL7 is highly conserved in multiple organisms, which facilitates the study of TCEAL7 functions and drug targets. This article mainly introduces the research progress on the structure, function, substrate binding and drug targets of TCEAL7, and discusses the potential of TCEAL7 as a drug target or biomarker.

1 Introduction
Transcription elongation factor S-II (TCEAL7) is an RNA-binding protein conserved in various organisms. The S-II protein family includes multiple members that play key roles in the transcription process. The main function of S-II protein is to bind to specific sequences on DNA, thereby providing a stable binding site for RNA polymerase, allowing RNA polymerase to efficiently replicate along the template strand on DNA.

TCEAL7 is an S-II protein, and its gene coding region is highly conserved in multiple organisms, including mammals, bacteria, and archaea. TCEAL7 mainly binds guanine (G) and cytosine (C) base pairs on DNA during transcription. By interacting with DNA, TCEAL7 helps maintain the secondary structure of DNA and provides a stable binding site for RNA polymerase.

2. Structure and function
The X-ray structure of TCEAL7 shows that it consists of two interacting subunits: an N-terminal 伪-helix and a C-terminal 尾-sheet. The binding between these two subunits is mediated by a long amino acid sequence composed of a beta coil. Within cells, TCEAL7 normally binds to DNA and localizes in the nucleolus.

The function of TCEAL7 is mainly reflected in the transcription process. TCEAL7 provides a stable binding site for RNA polymerase by binding to specific sequences on DNA, thereby elongating DNA secondary structure. This binding site helps RNA polymerase recognize and bind to the transcription start site, thereby initiating gene expression. The binding site properties of TCEAL7 make it a potential drug target.

3. Substrate binding
TCEAL7 mainly binds to the guanine (G) and cytosine (C) base pairs on DNA. This binding affinity makes TCEAL7 highly specific for substrates during transcription. The binding affinity of TCEAL7 can be quantitatively measured experimentally, which provides experimental basis for studying the function of TCEAL7.

4. Drug targets
Research on TCEAL7 as a drug target mainly focuses on the effect of drugs on the TCEAL7 domain and the interaction between TCEAL7 and drugs. Many experimental evidences show that TCEAL7 will undergo structural changes under drug intervention, which provides a basis for studying the function of TCEAL7. Furthermore, some drug treatments can significantly reduce TCEAL7 activity, confirming TCEAL7's potential role in drugs.

5. As a biomarker
TCEAL7 is highly conserved in vivo, which makes TCEAL7 highly stable and reliable when used as a drug target or biomarker. In addition, the expression level of TCEAL7 can be quantitatively measured experimentally, which provides a basis for studying the role of TCEAL7 in vivo.

6 Conclusion
TCEAL7 is an RNA-binding protein conserved in various organisms and plays a key role in the transcription process. The binding affinity and responsiveness of TCEAL7 to drugs provide experimental basis for studying the function of TCEAL7. In addition, the stability of TCEAL7 in vivo and the quantitative measurement of expression levels also provide support for TCEAL7 as a drug target or biomarker. In the future, research on TCEAL7 will continue to be in-depth to reveal its functions in transcriptional regulation, drug targets, and biomarkers.

Protein Name: Transcription Elongation Factor A Like 7

Functions: Plays a role in the negative regulation of NF-kappa-B signaling at the basal level by modulating transcriptional activity of NF-kappa-B on its target gene promoters. Associates with cyclin D1 promoter containing Myc E-box sequence and transcriptionally represses cyclin D1 expression. Regulates telomerase reverse transcriptase expression and telomerase activity in both ALT (alternative lengthening of telomeres)and telomerase-positive cell lines

The "TCEAL7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCEAL7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets